These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10350687)

  • 1. Intermittent blood pressure control: Potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15(Suppl C):13C-18C. PubMed ID: 10350687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent blood pressure control: potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15 Suppl C():13C-18C. PubMed ID: 10380687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
    Leenen FH; Myers MG; Joyner CD; Toal CB
    Can J Cardiol; 2002 Dec; 18(12):1285-93. PubMed ID: 12518180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients.
    Leenen FH
    J Hypertens Suppl; 1998 Oct; 16(5):S9-15. PubMed ID: 9868999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].
    Pede S; Lombardo M
    Ital Heart J Suppl; 2001 Apr; 2(4):356-8. PubMed ID: 19397006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy.
    Deedwania PC
    Cardiol Clin; 2005 May; 23(2):139-52. PubMed ID: 15694743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blockade in the challenging era of systolic hypertension.
    Stergiou GS
    J Hum Hypertens; 2004 Dec; 18(12):837-47. PubMed ID: 15318161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.